This site is intended for healthcare professionals
EMC Drug Feed
Drug information

Boots Dual Action Athletes Foot Cream

OTC
Read time: 1 mins
Last updated: 07 Jan 2021
...
 

Summary of product characteristics


1. Name of the medicinal product

Boots Athlete's Foot Cream


2. Qualitative and quantitative composition

Active ingredient

Quantity

Tolnaftate BP

1.0%w/w

Benzalkonium chloride solution BP

0.2%v/w


3. Pharmaceutical form

Cream


4.1. Therapeutic indications

Boots Dual Action Athlete's Foot Cream is indicated for the treatment and prevention of Athlete's Foot (Tinea Pedis). It is also effective in other conditions, such as Dhobie Itch (Tinea Cruris).


4.2. Posology and method of administration

Adults, children and the elderly: The affected area should be treated morning and night. Treatment should continue for at least a week after the infection has cleared.


4.3. Contraindications

Hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

Keep all medicines out of the reach of children.

For external use only.

If symptoms persist consult your doctor.


4.5. Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions known.


4.6. Fertility, pregnancy and lactation

No special requirements.


4.7. Effects on ability to drive and use machines

No adverse effects known.


4.8. Undesirable effects

Occasionally may cause skin irritation, hypersensitivity and contact dermatitis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.


4.9. Overdose

Not applicable.


5.1. Pharmacodynamic properties

Tolnaftate is a well established drug substance having potent antifungal properties.

Benzalkonium chloride is a well established drug substance having potent anti-microbial properties.


5.2. Pharmacokinetic properties

Not applicable.


5.3. Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.


6.1. List of excipients

Arlatone 983S

Cetostearyl alcohol

Dimethicone 20

Liquid paraffin

Glycerol

Purified water


6.2. Incompatibilities

Not applicable.


6.3. Shelf life

18 months


6.4. Special precautions for storage

Store in a cool place below 25°C.


6.5. Nature and contents of container

An internally lacquered metal tube with blind end nozzle. Tube to contain 25gm or 35gm.


6.6. Special precautions for disposal and other handling

None


7. Marketing authorisation holder

The Boots Company PLC

1 Thane Road West

Nottingham NG2 3AA


8. Marketing authorisation number(s)

PL0014/0457


9. Date of first authorisation/renewal of the authorisation

12 April 1994


10. Date of revision of the text

04 December 2018

4.1 Therapeutic indications

Boots Dual Action Athlete's Foot Cream is indicated for the treatment and prevention of Athlete's Foot (Tinea Pedis). It is also effective in other conditions, such as Dhobie Itch (Tinea Cruris).

4.2 Posology and method of administration

Adults, children and the elderly: The affected area should be treated morning and night. Treatment should continue for at least a week after the infection has cleared.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

Keep all medicines out of the reach of children.

For external use only.

If symptoms persist consult your doctor.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions known.

4.6 Fertility, pregnancy and lactation

No special requirements.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

Occasionally may cause skin irritation, hypersensitivity and contact dermatitis.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Drug section

Clinical trials
Clinical trial
Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.

2 mins
Clinical trial
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)

This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.

2 min
Clinical trial
A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (HiTS)

The purpose of this study is to determine whether ustekinumab is effective in the treatment of moderate to severe hidradenitis...

1 min
Journals
Journal
Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions

Objective: We sought to evaluate the efficacy and patient satisfaction of the deroofing technique for recurrent Hurley I (mild) or II (moderate) graded HS lesions at fixed locations.

1 mins
Journal
Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management

<p>The recognition of the central role of interleukin 17A (IL-17A) in the pathogenesis of psoriasis has led to the development of several monoclonal antibodies targeting this cytokine or its receptors for therapeutic purposes.</p>

1 min
Journal
Morbidity in patients with hidradenitis suppurativa

Objectives: To measure the impairment of life quality in patients with HS.

1 min
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).